Physician profile
Robert D Lerner
NPI 1295783181
$3,237.61
in general payments reported to CMS, 2019-2025
31 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $186 · 2021: $751 · 2022: $360 · 2023: $590 · 2024: $621 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,171.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.65 | 2019-2023 | Trulance |
| Janssen Biotech, INC. | $332.93 | 2019-2024 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $200.32 | 2024-2025 | Resmetirom, Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $152.76 | 2019-2021 | |
| Celgene Corporation | $116.05 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $113.63 | 2023 | Zeposia |
| Gilead Sciences, INC. | $83.82 | 2023-2024 | |
| Olympus America INC. | $79.62 | 2023-2025 | Endoclot Phs, Evis Exera III Colonovideoscope, Endoclot Sis |
| Ironwood Pharmaceuticals, INC | $75.90 | 2020-2022 | |
| Ardelyx, INC. | $73.73 | 2023 | Ibsrela |
| Lilly USA, LLC | $64.65 | 2023-2025 | Omvoh |
| Pfizer INC. | $59.88 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $45.34 | 2021-2022 | |
| Braintree Laboratories, INC. | $39.23 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $33.98 | 2019 | |
| Cook Medical LLC | $29.32 | 2023 | Hemospray |
| Jazz Pharmaceuticals INC. | $22.97 | 2024 | |
| Genzyme Corporation | $19.45 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.78 | 2025 | Rebyota |
| Amgen INC. | $17.68 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.59 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.53 | 2025 | Opsynvi, Uptravi |
| United Therapeutics Corporation | $17.35 | 2024 | Remodulin, Orenitram |
| Merck Sharp & Dohme LLC | $17.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.12 | 2023 | Cyltezo |
| Evoke Pharma, INC. | $13.54 | 2022 | |
| Allergan, INC. | $12.53 | 2019 | |
| Redhill Biopharma INC. | $12.11 | 2021 | |
| Intercept Pharmaceuticals, INC. | $12.00 | 2020 | |
| Romark Laboratories, Lc | $3.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.